319 related articles for article (PubMed ID: 25733135)
1. Role of sGC-dependent NO signalling and myocardial infarction risk.
Wobst J; Kessler T; Dang TA; Erdmann J; Schunkert H
J Mol Med (Berl); 2015 Apr; 93(4):383-94. PubMed ID: 25733135
[TBL] [Abstract][Full Text] [Related]
2. Dysfunctional nitric oxide signalling increases risk of myocardial infarction.
Erdmann J; Stark K; Esslinger UB; Rumpf PM; Koesling D; de Wit C; Kaiser FJ; Braunholz D; Medack A; Fischer M; Zimmermann ME; Tennstedt S; Graf E; Eck S; Aherrahrou Z; Nahrstaedt J; Willenborg C; Bruse P; Brænne I; Nöthen MM; Hofmann P; Braund PS; Mergia E; Reinhard W; Burgdorf C; Schreiber S; Balmforth AJ; Hall AS; Bertram L; Steinhagen-Thiessen E; Li SC; März W; Reilly M; Kathiresan S; McPherson R; Walter U; ; Ott J; Samani NJ; Strom TM; Meitinger T; Hengstenberg C; Schunkert H
Nature; 2013 Dec; 504(7480):432-6. PubMed ID: 24213632
[TBL] [Abstract][Full Text] [Related]
3. Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases.
Dupont LL; Glynos C; Bracke KR; Brouckaert P; Brusselle GG
Pulm Pharmacol Ther; 2014 Oct; 29(1):1-6. PubMed ID: 25043200
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes.
Wang H; Kohr MJ; Traynham CJ; Ziolo MT
J Mol Cell Cardiol; 2009 Aug; 47(2):304-14. PubMed ID: 19345227
[TBL] [Abstract][Full Text] [Related]
5. Human soluble guanylate cyclase as a nitric oxide sensor for NO-signalling reveals a novel function of nitrite reductase.
Pan J; Xu Q; Lin YW; Zhong F; Tan X
Chem Commun (Camb); 2013 Aug; 49(67):7454-6. PubMed ID: 23864033
[TBL] [Abstract][Full Text] [Related]
6. Impaired iNOS-sGC-cGMP signalling contributes to chronic hypoxic and hypercapnic pulmonary hypertension in rat.
Xia XD; Xu ZJ; Hu XG; Wu CY; Dai YR; Yang L
Cell Biochem Funct; 2012 Jun; 30(4):279-85. PubMed ID: 22290599
[TBL] [Abstract][Full Text] [Related]
7. Structure and regulation of soluble guanylate cyclase.
Derbyshire ER; Marletta MA
Annu Rev Biochem; 2012; 81():533-59. PubMed ID: 22404633
[TBL] [Abstract][Full Text] [Related]
8. Targeted genomic disruption of h-ras induces hypotension through a NO-cGMP-PKG pathway-dependent mechanism.
Chamorro-Jorganes A; Grande MT; Herranz B; Jerkic M; Griera M; Gonzalez-Nuñez M; Santos E; Rodriguez-Puyol D; Lopez-Novoa JM; Rodriguez-Puyol M
Hypertension; 2010 Sep; 56(3):484-9. PubMed ID: 20679183
[TBL] [Abstract][Full Text] [Related]
9. Regulation of nitric oxide-sensitive guanylyl cyclase.
Friebe A; Koesling D
Circ Res; 2003 Jul; 93(2):96-105. PubMed ID: 12881475
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical and functional characterization of nitric oxide signaling pathway in isolated aorta from Crotalus durissus terrificus.
Mónica FZ; Rojas-Moscoso J; Porto M; Schenka AA; Antunes E; Cogo JC; De Nucci G
Comp Biochem Physiol C Toxicol Pharmacol; 2012 Apr; 155(3):433-9. PubMed ID: 22134054
[TBL] [Abstract][Full Text] [Related]
11. What is next in nitric oxide research? From cardiovascular system to cancer biology.
Bian K; Murad F
Nitric Oxide; 2014 Dec; 43():3-7. PubMed ID: 25153032
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide mediates lymphatic vessel activation via soluble guanylate cyclase alpha1beta1-impact on inflammation.
Kajiya K; Huggenberger R; Drinnenberg I; Ma B; Detmar M
FASEB J; 2008 Feb; 22(2):530-7. PubMed ID: 17855621
[TBL] [Abstract][Full Text] [Related]
13. The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP.
Francis SH
Circ Res; 2010 Nov; 107(10):1164-6. PubMed ID: 21071713
[No Abstract] [Full Text] [Related]
14. NO (nitric oxide): the ring master.
Sinha S; Sridhara SR; Srinivasan S; Muley A; Majumder S; Kuppusamy M; Gupta R; Chatterjee S
Eur J Cell Biol; 2011 Jan; 90(1):58-71. PubMed ID: 20800929
[TBL] [Abstract][Full Text] [Related]
15. Formalin injection causes a coordinated spinal cord CO/NO-cGMP signaling system response.
Shi X; Li X; Clark JD
Mol Pain; 2005 Nov; 1():33. PubMed ID: 16297238
[TBL] [Abstract][Full Text] [Related]
16. Handbook of Experimental Pharmacology 191. cGMP: generators, effectors and therapeutic implications. Preface.
Schmidt HH; Hofmann F; Stasch JP
Handb Exp Pharmacol; 2009; (191):v-vi. PubMed ID: 19192509
[No Abstract] [Full Text] [Related]
17. The alpha2beta1 isoform of guanylyl cyclase mediates plasma membrane localized nitric oxide signalling.
Bellingham M; Evans TJ
Cell Signal; 2007 Oct; 19(10):2183-93. PubMed ID: 17643962
[TBL] [Abstract][Full Text] [Related]
18. Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes.
Castro LR; Schittl J; Fischmeister R
Circ Res; 2010 Nov; 107(10):1232-40. PubMed ID: 20847310
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Sertoli cell tight junction dynamics in the rat testis via the nitric oxide synthase/soluble guanylate cyclase/3',5'-cyclic guanosine monophosphate/protein kinase G signaling pathway: an in vitro study.
Lee NP; Cheng CY
Endocrinology; 2003 Jul; 144(7):3114-29. PubMed ID: 12810568
[TBL] [Abstract][Full Text] [Related]
20. Nucleotidyl cyclase activity of soluble guanylyl cyclase in intact cells.
Bähre H; Danker KY; Stasch JP; Kaever V; Seifert R
Biochem Biophys Res Commun; 2014 Jan; 443(4):1195-9. PubMed ID: 24380860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
